Gilder Gagnon Howe & Co. LLC acquired a new position in Magenta Therapeutics Inc (NASDAQ:MGTA) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,829,228 shares of the company’s stock, valued at approximately $30,127,000. Gilder Gagnon Howe & Co. LLC owned about 0.05% of Magenta Therapeutics as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of MGTA. Casdin Capital LLC grew its holdings in shares of Magenta Therapeutics by 17.4% in the fourth quarter. Casdin Capital LLC now owns 2,643,317 shares of the company’s stock valued at $15,067,000 after acquiring an additional 392,499 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Magenta Therapeutics by 224.2% in the fourth quarter. BlackRock Inc. now owns 556,381 shares of the company’s stock valued at $3,170,000 after acquiring an additional 384,752 shares in the last quarter. Harvard Management Co. Inc. grew its holdings in shares of Magenta Therapeutics by 23.7% in the fourth quarter. Harvard Management Co. Inc. now owns 411,379 shares of the company’s stock valued at $2,345,000 after acquiring an additional 78,769 shares in the last quarter. Bessemer Group Inc. bought a new position in shares of Magenta Therapeutics in the fourth quarter valued at approximately $1,352,000. Finally, Vanguard Group Inc grew its holdings in shares of Magenta Therapeutics by 92.6% in the third quarter. Vanguard Group Inc now owns 144,456 shares of the company’s stock valued at $1,735,000 after acquiring an additional 69,456 shares in the last quarter. 63.62% of the stock is owned by hedge funds and other institutional investors.
In other Magenta Therapeutics news, Director Bruce Booth sold 14,245 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $17.86, for a total transaction of $254,415.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by corporate insiders.
Shares of NASDAQ MGTA opened at $14.36 on Monday. Magenta Therapeutics Inc has a 1-year low of $5.31 and a 1-year high of $21.00. The firm has a market cap of $483.21 million and a price-to-earnings ratio of -4.59.
Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.11. On average, equities research analysts predict that Magenta Therapeutics Inc will post -2.03 EPS for the current year.
Several equities analysts have weighed in on the company. Zacks Investment Research lowered Magenta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Magenta Therapeutics in a report on Friday, May 10th. Goldman Sachs Group lowered Magenta Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $17.00 to $16.00 in a report on Sunday, March 24th. They noted that the move was a valuation call. Finally, Raymond James assumed coverage on Magenta Therapeutics in a report on Thursday, March 14th. They set an “outperform” rating for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $19.00.
ILLEGAL ACTIVITY WARNING: “Gilder Gagnon Howe & Co. LLC Acquires New Position in Magenta Therapeutics Inc (NASDAQ:MGTA)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2019/06/17/gilder-gagnon-howe-co-llc-acquires-new-position-in-magenta-therapeutics-inc-nasdaqmgta.html.
Magenta Therapeutics Profile
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Featured Article: What are the benefits of investing in REITs?
Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.